Disclosures for "Highly Prevalent but Mild Neuropathic Burden in Wild-type Transthyretin Amyloidosis"
-
Dr. Bareja has nothing to disclose.
-
Dr. Bartkus has nothing to disclose.
-
Mr. Patel has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Soto has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. The institution of Dr. Soto has received research support from CTSI.
-
The institution of Dr. Riesenburger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zeneca. The institution of Dr. Riesenburger has received research support from NIH. The institution of Dr. Riesenburger has received research support from Tufts.